Trump signs executive actions to boost domestic drug manufacturing and tighten oversight on gain-of-function research, raising concerns over potential higher costs and shortages.
OpenAI reverses course, retains nonprofit board control and converts to a Public Benefit Corporation to balance profit-making and its charitable mission.
Henry Schein misses Q1 revenue, but KKR takes stake, influencing board composition amid operational challenges.
Trump signs executive actions to boost domestic drug manufacturing and tighten oversight on gain-of-function research, raising concerns over potential higher costs and shortages.
OpenAI reverses course, retains nonprofit board control and converts to a Public Benefit Corporation to balance profit-making and its charitable mission.
Henry Schein misses Q1 revenue, but KKR takes stake, influencing board composition amid operational challenges.